Molecular characterization of Staphylococcus aureus isolates from a 2005 clinical trial of uncomplicated skin and skin structure infections.
A clinical trial of uncomplicated skin and skin structure infections (39 locations in 19 states) observed that community-associated or community-onset methicillin-resistant Staphylococcus aureus (CO-MRSA) represented 23% of all pathogens at baseline culture and 53% of 190 S. aureus isolates. CO-MRSA strains typically were Panton-Valentine leukocidin (PVL) positive (95%), contained staphylococcal cassette chromosome mec type IVa (99%), were USA300 or USA400 clones (92%), and exhibited minimal coresistances (macrolides and/or fluoroquinolones). Clinical results remained identical (89% cures) regardless of the antimicrobial used or CO-MRSA molecular patterns, PVL production, or antimicrobial susceptibility profiles.
Jones
Ronald N
RN
JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, Iowa 52317, USA. ronald-jones@jmilabs.com
Nilius
Angela M
AM
Akinlade
Bolanle K
BK
Deshpande
Lalitagauri M
LM
Notario
Gerard F
GF
D001426:Bacterial Proteins / Q000235:genetics; D001427:Bacterial Toxins / Q000378:metabolism; D002986:Clinical Trials as Topic; D017714:Community-Acquired Infections / Q000382:microbiology; D016521:Electrophoresis, Gel, Pulsed-Field; D005098:Exotoxins / Q000378:metabolism; D006801:Humans; D007956:Leukocidins / Q000378:metabolism; D016106:Methicillin Resistance / Q000235:genetics; D015337:Multicenter Studies as Topic; D046915:Penicillin-Binding Proteins; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012874:Skin Diseases, Infectious / Q000382:microbiology*; D013203:Staphylococcal Infections / Q000453:epidemiology / Q000382:microbiology; D013211:Staphylococcus aureus / Q000187:drug effects / Q000235:genetics*
D001426:Bacterial Proteins; D001427:Bacterial Toxins; D005098:Exotoxins; D007956:Leukocidins; C078284:Panton-Valentine leukocidin; D046915:Penicillin-Binding Proteins; C487789:mecA protein, Staphylococcus aureus